|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cardiovascular Diseases | |||||
| Carotid Stenosis | |||||
| Cerebral Arteriosclerosis | |||||
| Cerebrovascular Disorders | |||||
| Heart Diseases | |||||
| Vascular Diseases | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Arteriosclerosis | |||||
| Intracranial Arteriosclerosis | |||||
| 3 | More general conditions related to this trial | ||||
| Arterial Occlusive Diseases | |||||
| Brain Diseases | |||||
| Carotid Artery Diseases | |||||
| Central Nervous System Diseases | |||||
| Intracranial Arterial Diseases | |||||
| Nervous System Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| aspirin | |||||
| lovastatin | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anticholesteremic Agents | |||||
| Antilipemic Agents | |||||
| Antimetabolites | |||||
| Enzyme Inhibitors | |||||
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Heart, Lung, and Blood Institute (NHLBI) | |||||